# Clinical Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) Against COVID-19

> **NCT04540419** · PHASE3 · COMPLETED · sponsor: **NPO Petrovax** · enrollment: 500 (actual)

## Conditions studied

- Covid19

## Interventions

- **BIOLOGICAL:** Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT04540419
- **Lead sponsor:** NPO Petrovax
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-09-11
- **Primary completion:** 2021-06-19
- **Final completion:** 2021-07-30
- **Target enrollment:** 500 (ACTUAL)
- **Last updated:** 2024-04-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04540419

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04540419, "Clinical Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) Against COVID-19". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04540419. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*